Efficacy and safety of low-dose everolimus in Chinese HR-positive, HER2-negative metastatic breast cancer patients.

被引：1
|
作者：
Shao, Xiying
Zheng, Yabing
Chen, Zhan-Hong
Li, Guangliang
Jia, Wang Xiao
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[2] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e13035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13035
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy of fulvestrant-based therapies in treating HR-positive, HER2-negative breast cancer with liver metastasis
    Chien, Christine
    Madak-Erdogan, Zeynep
    Goel, Mahima
    Gangidi, Suma
    Tripathy, Debu
    Raghavendra, Akshara Singareeka
    CANCER RESEARCH, 2023, 83 (05)
  • [32] AN INCREMENTAL EFFECTIVENESS ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER IN PORTUGAL
    Pinheiro, B.
    Paquete, A. T.
    Sousa, R.
    Ines, M.
    Gouveia, M.
    Borges, M.
    VALUE IN HEALTH, 2020, 23 : S529 - S529
  • [33] A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative)
    Rugo, Hope S.
    Bardia, Aditya
    Marme, Frederik
    Cortes, Javier
    Schmid, Peter
    Spears, Patricia A.
    Tolaney, Sara M.
    FUTURE ONCOLOGY, 2024, 20 (11) : 635 - 651
  • [34] The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer
    Huang, Jia-Yi
    Chen, Xue-Lian
    Xie, Xiao-Feng
    Song, Lin
    Chen, Li-Ping
    Lan, Xiao-Feng
    Bai, Xue
    Chen, Xiao
    Du, Cai-Wen
    CANCER MEDICINE, 2024, 13 (08):
  • [35] A prospective phase II study on efficacy and safety of anlotinib combined with fulvestrant in patients with HR-positive and HER2-negative, secondary endocrine-resistant, locally advanced or metastatic breast cancer
    Wang, Xiaojia
    Huang, Jian
    CANCER RESEARCH, 2022, 82 (04)
  • [36] SAFETY AND EFFICACY OF MAINTENANCE BEVACIZUMAB IN HER2-NEGATIVE METASTATIC BREAST CANCER
    Russillo, M.
    Metro, G.
    Giannarelli, D.
    Papaldo, P.
    Nistico, C.
    Ferretti, G.
    Cuppone, F.
    D'Auria, G.
    Cognetti, F.
    Fabi, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 105 - 105
  • [37] Association of KAT6A expression with clinical outcomes in previously treated HR-positive and HER2-negative metastatic breast cancer
    Cristofanilli, Massimo
    Liu, Li
    Deng, Shibing
    Huang, Xin
    Andre, Fabrice
    Loibl, Sibylle
    DeMichele, Angela
    Gauthier, Eric
    Liu, Yuan
    Turner, Nicholas C.
    CANCER RESEARCH, 2024, 84 (06)
  • [38] A phase II trial of anlotinib and fulvestrant in patients with HR-positive and HER2-negative, secondary aromatase inhibitor-resistant, metastatic breast cancer
    Wang, Xiaojia
    Huang, Jian
    Chen, Wenyan
    Sun, Zhengkui
    Liu, Jian
    Cui, Jiuwei
    Wei, Songzhi
    Lv, Zheng
    Wu, Fan
    Yu, Tenghua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Efficacy of everolimus plus exemestane in CDK 4/6 inhibitors-pretreated or naive HR-positive/HER2-negative breast cancer patients: A secondary analysis of the EVERMET study
    Nichetti, F.
    Marra, A.
    Giorgi, C. A.
    Randon, G.
    Scagnoli, S.
    De Angelis, C.
    Molinelli, C.
    Ferraro, E.
    Trapani, D.
    Milani, A.
    Agostinetto, E.
    Bernocchi, O.
    Catania, G.
    Rea, C. G.
    Basile, D.
    Gerratana, L.
    Cinausero, M.
    Vernieri, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S382 - S382
  • [40] Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study
    Wu, Yun
    Mo, Hongnan
    Xu, Hangcheng
    Wang, Yan
    Wang, Jiayu
    Ma, Fei
    Xu, Binghe
    THORACIC CANCER, 2024, 15 (12) : 965 - 973
12345